James Siegert, DO
Urology · Olympia Fields, ILNPI 1245556224
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $23,829 of the $36,589 with a category attached, or 65.1%. 31 manufacturers reported payments, led by Boston Scientific at 57.3% of the total. Reporting peaked in 2019 at $11,901 and has fallen 79.4% since, to $2,448 in 2025. Among urology clinicians in IL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 234 payments — averaging $156.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$21K
- Astellas Pharma US Inc$12K
- AbbVie$977
- Stryker$750
- Axonics, Inc.$466
- Medtronic$396
- plus $1K from 25 others
What the payments were for
- Consulting fees$2,2466%
- Speaking & faculty fees$23,82965%
- Travel & lodging$2,5677%
- Food & beverage$7,41220%
- Education$5351%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 79 | $20,956 |
| Astellas Pharma US Inc | 47 | $11,610 |
| AbbVie(2 entities) | 38 | $977 |
| Stryker | 1 | $750 |
| Axonics, Inc. | 19 | $466 |
| Medtronic | 1 | $396 |
| C. R. Bard, Inc. & Subsidiaries | 8 | $233 |
| Intuitive Surgical | 2 | $190 |
| AstraZeneca | 7 | $135 |
| Valencia Technologies Corporation | 2 | $133 |
| Comsort, Inc | 1 | $100 |
| Johnson & Johnson | 3 | $77 |
| BD | 3 | $71 |
| Progenics Pharmaceuticals, Inc. | 2 | $53 |
| Rochester Medical Corporation | 2 | $53 |
| Olympus America Inc. | 3 | $47 |
| Merck | 2 | $34 |
| Dendreon Pharmaceuticals LLC | 1 | $33 |
| Agiliti Surgical, Inc. | 1 | $33 |
| Telix Pharmaceuticals | 1 | $30 |
| Laborie Medical Technologies Corp. | 1 | $29 |
| Sumitomo Pharma America, Inc. | 1 | $25 |
| Myovant Sciences Inc. | 1 | $24 |
| Myriad Genetic Laboratories, Inc. | 1 | $23 |
| Tolmar Pharmaceuticals, Inc. | 1 | $19 |
| Pfizer | 1 | $19 |
| Biolase, Inc. | 1 | $19 |
| Endo Pharmaceuticals Inc. | 1 | $17 |
| Antares Pharma, Inc. | 1 | $17 |
| Bayer | 1 | $14 |
| Ambu Inc. | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MYRBETRIQ$10,135
- GENERAL KIDNEY STONE DISEASE$3,563
- LithoVue$2,698
- EXPORT AP$396
- AMS$358
- SpaceOAR VUE System - 10mL$315
- AMS 700$243
- XTANDI$235
- DA VINCI SP$150
- Axonics$129
- Bulkamid$129
- Axonics r-SNM System$124
- eCoin Device Kit$122
- AMS 700 CXR RTE KIT$110
- KEYTRUDA$100
How this compares
$36,589 in reported general payments places this provider in the 90th percentile of 550 urology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 49 | $717,572 |
| MyrbetriqMirabegron | 400 | $270,442 |
| Mirabegron ErMirabegron | 77 | $40,008 |
| OrgovyxRelugolix | 13 | $34,909 |
| GemtesaVibegron | 43 | $33,323 |
| XyostedTestosterone Enanthate | 36 | $22,037 |
| PremarinEstrogens, Conjugated | 34 | $16,171 |
| Tamsulosin Hcl | 1,321 | $16,020 |
| Potassium Citrate ErPotassium Citrate | 84 | $7,023 |
| Finasteride | 450 | $6,605 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 193 | $3,002 |
| Oxybutynin Chloride ErOxybutynin Chloride | 179 | $2,814 |
| Silodosin | 27 | $2,541 |
| Estradiol | 31 | $1,964 |
| Desmopressin Acetate | 13 | $1,310 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $11,610 | $988,014449 claims |
| Sumitomo Pharma America, Inc.Orgovyx, Gemtesa | $25 | $68,23256 claims |
| Antares Pharma, Inc.Xyosted | $17 | $22,03736 claims |
| PfizerPremarin | $19 | $16,17134 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 550 urology providers in Illinois.
Other urology in Olympia Fields
- Mark BrandtPark Ridge$1.3M
- Aaron BergerChicago Ridge$583K
- Gary SteinbergChicago$529K
- Simone CrivellaroChicago$526K
- Brian HelfandChicago$517K
- Ashley RossChicago$404K
- Kevin McVarySpringfield$372K
- Richard HarrisMelrose Park$363K
- Amy KrambeckChicago$356K
- Kevin ZornChicago$274K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.